ICN2 and CSIC Spin-off INBRAIN Neuroelectronics Raises $50 Million Series B Funding

by Chema Arcos

This major investment will accelerate the development of its graphene-based therapeutic neural interfaces.

INBRAIN Neuroelectronics, an innovative ICN2 and CSIC spin-off dedicated to the development of brain-computer interfaces for neurological therapies, has announced a Series B $50 million funding round led by Imec.Xpand. This extraordinary investment will enable the company to advance its clinical trials and accelerate the development of its neurosensing and neuromodulation technology. In addition to this round, INBRAIN has also received funding and resources from Merck KGaA to advance the clinical development of its technology across multiple therapeutic areas. This brings the total investment in INBRAIN since its inception to $68 million.

INBRAIN has developed a unique technology that uses graphene, a very thin (1 atom thick), flexible and resistant material, to decode and modulate neural signals with high precision. This technology has shown huge potential for the treatment of neurological disorders such as Parkinson's disease and epilepsy. The company's graphene-based brain-computer interfaces (BCI) is currently being tested in a clinical trial to demonstrate safety when implanted, and their ability to decode neural signals during brain tumour resection surgery.

With this round of funding, INBRAIN will be able to continue ongoing clinical trials and expand its team to bring its pioneer technology to market. As part of the financing round, INBRAIN has also announced a strategic collaboration with Imec, a European leader in semiconductors technology, to progress through the commercialisation of this technology.

INBRAIN emphasises that this investment will be a key factor in the future development of its technology. In addition, this support and confidence from investors reaffirm its mission to continue working to provide more precise, personalised and safer treatments for a range of neurological disorders.

This important funding, together with the start of human trials, represents a breakthrough for INBRAIN as well as for ICN2. Our Institute continues to position itself as a key player in advanced neurotechnology research.